English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In western countries, renal cell carcinoma (RCC) has become the seventh-largest tumor in men and the third most common malignant tumor of the genitourinary system; its incidence is increasing at 2–4% (1,2). RCC includes a variety of histological types. CcRCC is the most aggressive, carries the poorest outcome, and is the most common, accounting for nearly 90% of all malignant renal tumors (1,3). About 30% of RCC patients had advanced disease at the initial diagnosis; the 5-year survival rate was only 11% (4). Chemotherapy or radiotherapy does not affect CcRCC, and the overall clinical effect is not good (5,6). There are surgical and targeted therapies for the treatment of RCC that improve the overall survival rate of patients (7). However, most patients eventually died of the disease because of the ineffective treatment. Therefore, there is an urgent need to use diagnostic and prognostic biomarkers in ccRCC. Nevertheless, to the best of our knowledge, ccRCC has no biomarkers used in routine Original Article

Construction of five microRNAs prognostic markers and a prognostic model for clear cell renal cell carcinoma